

SAFETY DATA SHEET



Letermovir Solid Formulation

Version 6.1 Revision Date: 14.04.2025 SDS Number: 58429-00027 Date of last issue: 06.04.2024
Date of first issue: 16.02.2015

Section 1: Identification

Product identifier : Letermovir Solid Formulation

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

Manufacturer or supplier's details

Company : MSD

Address : 50 Tuas West Drive
Singapore - Singapore 638408

Telephone : +1-908-740-4000

Emergency telephone number : 65 6697 2111 (24/7/365)

E-mail address : EHSDATASTEWARD@msd.com

Section 2: Hazard identification

Classification of the substance or mixture

Reproductive toxicity : Category 2

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Liver, spleen, Blood)

GHS Label elements, including precautionary statements

Hazard pictograms :



Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.
H373 May cause damage to organs (Liver, spleen, Blood) through prolonged or repeated exposure if swallowed.

Precautionary statements :

Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P260 Do not breathe dust.

P280 Wear protective gloves/ protective clothing/ eye protec-

SAFETY DATA SHEET



Letermovir Solid Formulation

| | | | |
|----------------|------------------------------|----------------------------|---|
| Version 6.1 | Revision Date: 14.04.2025 | SDS Number: 58429-00027 | Date of last issue: 06.04.2024 Date of first issue: 16.02.2015 |
|----------------|------------------------------|----------------------------|---|

tion/ face protection/ hearing protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|--------------------|-------------|-----------------------|
| Cellulose | 9004-34-6 | >= 30 -< 50 |
| Letermovir | 917389-32-3 | >= 30 -< 50 |
| Magnesium stearate | 557-04-0 | >= 1 -< 10 |

Section 4: First-aid measures

Description of necessary first-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed

Risks : Contact with dust can cause mechanical irritation or drying of

SAFETY DATA SHEET



Letermovir Solid Formulation

Version 6.1 Revision Date: 14.04.2025 SDS Number: 58429-00027 Date of last issue: 06.04.2024 Date of first issue: 16.02.2015

the skin.
Dust contact with the eyes can lead to mechanical irritation.
Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides
Nitrogen oxides (NO_x)

Special protective actions for fire-fighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Letermovir Solid Formulation

| | | | |
|----------------|------------------------------|----------------------------|---|
| Version 6.1 | Revision Date: 14.04.2025 | SDS Number: 58429-00027 | Date of last issue: 06.04.2024 Date of first issue: 16.02.2015 |
|----------------|------------------------------|----------------------------|---|

Environmental precautions

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage**Precautions for safe handling**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment,

SAFETY DATA SHEET



Letermovir Solid Formulation

| | | | |
|----------------|------------------------------|----------------------------|---|
| Version 6.1 | Revision Date: 14.04.2025 | SDS Number: 58429-00027 | Date of last issue: 06.04.2024 Date of first issue: 16.02.2015 |
|----------------|------------------------------|----------------------------|---|

appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage, including any incompatibilities

Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection

Control parameters

Occupational Exposure Limits

| Components | CAS-No. | Value type (Form of exposure) | Control parame- ters / Permissible concentration | Basis |
|--------------------|-------------|--|--|----------|
| Cellulose | 9004-34-6 | PEL (long term) | 10 mg/m ³ | SG OEL |
| | | TWA | 10 mg/m ³ | ACGIH |
| Letermovir | 917389-32-3 | TWA | 0.4 mg/m ³ (OEB 2) | Internal |
| Magnesium stearate | 557-04-0 | PEL (long term) | 10 mg/m ³ | SG OEL |
| | | TWA (Inhal- able particu- late matter) | 10 mg/m ³ | ACGIH |
| | | TWA (Res- pirable par- ticulate mat- ter) | 3 mg/m ³ | ACGIH |

Appropriate engineering control measures

: Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Individual protection measures, such as personal protective equipment (PPE)

Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin protection : Work uniform or laboratory coat.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

SAFETY DATA SHEET



Letermovir Solid Formulation

Version 6.1 Revision Date: 14.04.2025 SDS Number: 58429-00027 Date of last issue: 06.04.2024
Date of first issue: 16.02.2015

| | | |
|-----------------|---|--|
| | | sure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. |
| Filter type | : | Particulates type |
| Hand protection | : | Chemical-resistant gloves |
| Material | : | |

Section 9: Physical and chemical properties

| | | |
|--|---|---|
| Appearance | : | powder |
| Colour | : | No data available |
| Odour | : | No data available |
| Odour Threshold | : | No data available |
| pH | : | No data available |
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point | : | Not applicable |
| Evaporation rate | : | Not applicable |
| Flammability (solid, gas) | : | May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids) | : | No data available |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapour pressure | : | Not applicable |
| Relative vapour density | : | Not applicable |
| Relative density | : | No data available |
| Density | : | No data available |
| Solubility(ies) | | |
| Water solubility | : | No data available |
| Partition coefficient: n-octanol/water | : | Not applicable |
| Auto-ignition temperature | : | No data available |

SAFETY DATA SHEET



Letermovir Solid Formulation

Version 6.1 Revision Date: 14.04.2025 SDS Number: 58429-00027 Date of last issue: 06.04.2024
Date of first issue: 16.02.2015

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle characteristics
Particle size : No data available

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

Section 11: Toxicological information

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Letermovir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Letermovir Solid Formulation

| | | | |
|----------------|------------------------------|----------------------------|---|
| Version 6.1 | Revision Date: 14.04.2025 | SDS Number: 58429-00027 | Date of last issue: 06.04.2024 Date of first issue: 16.02.2015 |
|----------------|------------------------------|----------------------------|---|

LD50 (Mouse): > 2,000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:**Letermovir:**

Remarks : No data available

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Letermovir:**

Remarks : No data available

Magnesium stearate:

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

SAFETY DATA SHEET



Letermovir Solid Formulation

Version 6.1 Revision Date: 14.04.2025 SDS Number: 58429-00027 Date of last issue: 06.04.2024
Date of first issue: 16.02.2015

Components:

Letermovir:

Remarks : No data available

Magnesium stearate:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative
Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Letermovir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative

Letermovir Solid FormulationVersion
6.1Revision Date:
14.04.2025SDS Number:
58429-00027Date of last issue: 06.04.2024
Date of first issue: 16.02.2015

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:**Cellulose:**

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Letermovir:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, female
Application Route: Oral
Fertility: NOAEL: 240 mg/kg body weight
Result: No effects on fertility

Test Type: Fertility/early embryonic development
Species: Rat, male
Application Route: Oral
Fertility: LOAEL: 180 mg/kg body weight
Result: No effects on fertility

Remarks: The significance of these findings for humans is not

SAFETY DATA SHEET



Letermovir Solid Formulation

| | | | |
|----------------|------------------------------|----------------------------|---|
| Version 6.1 | Revision Date: 14.04.2025 | SDS Number: 58429-00027 | Date of last issue: 06.04.2024 Date of first issue: 16.02.2015 |
|----------------|------------------------------|----------------------------|---|

certain.

Test Type: Fertility/early embryonic development

Species: Monkey, male

Application Route: Oral

Fertility: NOAEL: 240 mg/kg body weight

Result: No effects on fertility

Effects on foetal development

- : Test Type: Embryo-foetal development
Species: Rat
Developmental Toxicity: LOAEL: 250 mg/kg body weight
Result: Embryo-foetal toxicity
Remarks: Maternal toxicity observed.

Test Type: Embryo-foetal development

Species: Rabbit

Developmental Toxicity: LOAEL: 225 mg/kg body weight
Result: Embryo-foetal toxicity, Malformations were observed.,
Abortion

Remarks: Maternal toxicity observed.

Reproductive toxicity - Assessment

- : Some evidence of adverse effects on development, based on animal experiments.

Magnesium stearate:

Effects on fertility

- : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development

- : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Liver, spleen, Blood) through prolonged or repeated exposure if swallowed.

Components:

Letermovir:

Exposure routes

- : Ingestion

Target Organs

- : Liver, spleen, Blood

Assessment

- : May cause damage to organs through prolonged or repeated

Letermovir Solid Formulation

| | | | |
|----------------|------------------------------|----------------------------|---|
| Version 6.1 | Revision Date: 14.04.2025 | SDS Number: 58429-00027 | Date of last issue: 06.04.2024 Date of first issue: 16.02.2015 |
|----------------|------------------------------|----------------------------|---|

exposure.

Repeated dose toxicity**Components:****Cellulose:**

| | | |
|-------------------|---|----------------|
| Species | : | Rat |
| NOAEL | : | >= 9,000 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 90 Days |

Letermovir:

| | | |
|-------------------|---|---------------|
| Species | : | Mouse |
| NOAEL | : | 40 mg/kg |
| LOAEL | : | 100 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 13 Weeks |
| Target Organs | : | Liver, spleen |

| | | |
|-------------------|---|--|
| Species | : | Rat |
| NOAEL | : | 150 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 26 Weeks |
| Remarks | : | No significant adverse effects were reported |

| | | |
|-------------------|---|-----------------|
| Species | : | Monkey |
| NOAEL | : | 100 mg/kg |
| LOAEL | : | 200 - 250 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 39 Weeks |
| Target Organs | : | Kidney |

| | | |
|---------------|---|---|
| Species | : | Rat |
| NOAEL | : | 60 mg/kg |
| LOAEL | : | 180 mg/kg |
| Exposure time | : | 13 Weeks |
| Target Organs | : | Testis, Blood, Liver, spleen, Immune system |

| | | |
|-------------------|---|-----------|
| Species | : | Monkey |
| NOAEL | : | 30 mg/kg |
| LOAEL | : | 100 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 4 Weeks |
| Target Organs | : | Blood |

Magnesium stearate:

| | | |
|-------------------|---|-------------|
| Species | : | Rat |
| NOAEL | : | > 100 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 90 Days |

SAFETY DATA SHEET



Letermovir Solid Formulation

| | | | |
|----------------|------------------------------|----------------------------|---|
| Version 6.1 | Revision Date: 14.04.2025 | SDS Number: 58429-00027 | Date of last issue: 06.04.2024 Date of first issue: 16.02.2015 |
|----------------|------------------------------|----------------------------|---|

Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Letermovir:

Ingestion : Symptoms: Diarrhoea, Nausea, Vomiting, Headache, Dizziness, Fatigue, Back pain, Oedema, Rash, muscle pain

Section 12: Ecological information

Toxicity

Components:

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Letermovir:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Americamysis): 16 mg/l
Exposure time: 96 h
EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 8.8 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 8.8 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 1 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Letermovir Solid Formulation

| | | | |
|----------------|------------------------------|----------------------------|---|
| Version 6.1 | Revision Date: 14.04.2025 | SDS Number: 58429-00027 | Date of last issue: 06.04.2024 Date of first issue: 16.02.2015 |
|----------------|------------------------------|----------------------------|---|

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 1.2 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 972 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 29.6 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Method: Directive 67/548/EEC, Annex V, C.2.
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Letermovir Solid Formulation

| | | | |
|----------------|------------------------------|----------------------------|---|
| Version 6.1 | Revision Date: 14.04.2025 | SDS Number: 58429-00027 | Date of last issue: 06.04.2024 Date of first issue: 16.02.2015 |
|----------------|------------------------------|----------------------------|---|

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Letermovir:

Biodegradability : Result: rapidly degradable
Biodegradation: 50 %
Exposure time: 6.7 d

Magnesium stearate:

Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential**Components:****Letermovir:**

Partition coefficient: n-octanol/water : log Pow: 2.29

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil**Components:****Letermovir:**

Distribution among environmental compartments : log Koc: 3.46

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations**

SAFETY DATA SHEET



Letermovir Solid Formulation

Version 6.1 Revision Date: 14.04.2025 SDS Number: 58429-00027 Date of last issue: 06.04.2024
Date of first issue: 16.02.2015

UNRTDG

UN number : Not applicable
UN proper shipping name : Not applicable
Transport hazard class(es) : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
UN proper shipping name : Not applicable
Transport hazard class(es) : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo aircraft) : Not applicable
Packing instruction (passenger aircraft) : Not applicable

IMDG-Code

UN number : Not applicable
UN proper shipping name : Not applicable
Transport hazard class(es) : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
EmS Code : Not applicable
Marine pollutant : Not applicable

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

Section 15: Regulatory information

Safety, health and environmental regulations specific for the product in question

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subject to the requirements in the Act/Regulations.

Environmental Protection and Management Act and : Not applicable
Environmental Protection and Management (Hazardous Substances) Regulations
Fire Safety (Petroleum and Flammable Materials) : Not applicable
Regulations

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined

SAFETY DATA SHEET



Letermovir Solid Formulation

Version 6.1 Revision Date: 14.04.2025 SDS Number: 58429-00027 Date of last issue: 06.04.2024 Date of first issue: 16.02.2015

IECSC : not determined

Section 16: Other information

Revision Date : 14.04.2025

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

SG OEL : Singapore. Workplace Safety and Health (General Provisions) Regulations - First Schedule Permissible Exposure Limits of Toxic Substances.

ACGIH / TWA : 8-hour, time-weighted average

SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recom-

SAFETY DATA SHEET



Letermovir Solid Formulation

| | | | |
|----------------|------------------------------|----------------------------|---|
| Version 6.1 | Revision Date: 14.04.2025 | SDS Number: 58429-00027 | Date of last issue: 06.04.2024 Date of first issue: 16.02.2015 |
|----------------|------------------------------|----------------------------|---|

mendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN